331647-05-3

Basic information

• Product Name: 8-BROMO-2,4-DICHLOROQUINAZOLINE
• Synonyms: 2,4-DICHLORO-8-BROMOQUINAZOLINE;8-BROMO-2,4-DICHLOROQUINAZOLINE;Quinazoline, 8-bromo-2,4-dichloro-
• CAS NO: 331647-05-3
• Molecular Formula: C8H3BrCl2N2
• Molecular Weight: 277.936
• Mol File: 331647-05-3.mol

Chemical Properties

• Boiling Point: 248.2 °C at 760 mmHg
• Flash Point: 103.9 °C
• Appearance: /
• Density: 1.851
• Vapor Pressure: 0.0388mmHg at 25°C
• Refractive Index: 1.696
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -1.75±0.30(Predicted)
• CAS DataBase Reference: 8-BROMO-2,4-DICHLOROQUINAZOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 8-BROMO-2,4-DICHLOROQUINAZOLINE(331647-05-3)
• EPA Substance Registry System: 8-BROMO-2,4-DICHLOROQUINAZOLINE(331647-05-3)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 331647-05-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
8-Bromo-2,4-dichloroquinazoline is used as a building block for the synthesis of complex molecules with potential pharmacological properties. Its unique structure and reactivity allow for further chemical modifications to enhance its biological activity and selectivity, making it a valuable component in the development of new drugs.
Used in Agrochemical Industry:
In the agrochemical field, 8-Bromo-2,4-dichloroquinazoline is used as a precursor in the synthesis of compounds with potential pesticidal or herbicidal properties. Its reactivity and the presence of halogen atoms contribute to the development of new agrochemicals with improved efficacy and selectivity.
Used in Material Sciences:
8-Bromo-2,4-dichloroquinazoline is utilized in material sciences for the development of novel materials with specific properties. Its unique structure and reactivity enable the creation of new compounds with potential applications in various industries, such as electronics, coatings, and polymers.
Used in Organic Chemistry Research:
As a highly reactive quinazoline derivative, 8-Bromo-2,4-dichloroquinazoline is used in organic chemistry research to explore new synthetic pathways, reaction mechanisms, and the development of innovative chemical processes. Its unique structure provides a platform for understanding and advancing the field of organic chemistry.

InChI:InChI=1/C8H3BrCl2N2/c9-5-3-1-2-4-6(5)12-8(11)13-7(4)10/h1-3H

Upstream product

• 20776-51-6 2-amino-3-bromo benzoic acid 
• 114344-60-4 2-amino-3-bromo-benzonitrile 
• 608-30-0 2,6-dibromoaniline 
• 331646-99-2 8-bromoquinazoline-2,4-(1H,3H)-dione 
• 331646-99-2 8-bromoquinazoline-2,4-diol 

Downstream Products

• 956100-62-2 8-bromo-2-chloroquinazolin-4-amine 

Relevant articles and documents

One-pot cascade ring enlargement of isatin-3-oximes to 2,4-dichloroquinazolines mediated by bis(trichloromethyl)carbonate and triarylphosphine oxide

An efficient and convenient one-pot cascade synthesis of 2,4-dichloroquinazolines directly from isatin-3-oximes with the addition of bis(trichloromethyl)carbonate and triarylphosphine oxide was developed, leading to substituted quinazolines in moderate to excellent yields. The efficiency of this transformation was demonstrated by compatibility with a range of functional groups. Thus, the method represents a convenient and practical strategy for the synthesis of substituted 2,4-dichloroquinazolines.

CD73 INHIBITORS

Disclosed are compounds that are inhibitors of CD73 and are useful in treating CD73-associated diseases or conditions, and compositions containing the compounds.

Discovery of (R)-8-(6-Methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4- b]pyrrol-2-yl)-3-(1-methylcyclopropyl)-2-((1-methylcyclopropyl)amino)quinazolin-4(3 H)-one, a Potent and Selective Pim-1/2 Kinase Inhibitor for Hematological Malignancies

Pim kinases are a family of constitutively active serine/threonine kinases that are partially redundant and regulate multiple pathways important for cell growth and survival. In human disease, high expression of the three Pim isoforms has been implicated in the progression of hematopoietic and solid tumor cancers, which suggests that Pim kinase inhibitors could provide patients with therapeutic benefit. Herein, we describe the structure-guided optimization of a series of quinazolinone-pyrrolodihydropyrrolone analogs leading to the identification of potent pan-Pim inhibitor 28 with improved potency, solubility, and drug-like properties. Compound 28 demonstrated on-target Pim activity in an in vivo pharmacodynamic assay with significant inhibition of BAD phosphorylation in KMS-12-BM multiple myeloma tumors for 16 h postdose. In a 2-week mouse xenograft model, daily dosing of compound 28 resulted in 33% tumor regression at 100 mg/kg.

Discovery of Quinazolines That Activate SOS1-Mediated Nucleotide Exchange on RAS

Proteins in the RAS family are important regulators of cellular signaling and, when mutated, can drive cancer pathogenesis. Despite considerable effort over the last 30 years, RAS proteins have proven to be recalcitrant therapeutic targets. One approach for modulating RAS signaling is to target proteins that interact with RAS, such as the guanine nucleotide exchange factor (GEF) son of sevenless homologue 1 (SOS1). Here, we report hit-to-lead studies on quinazoline-containing compounds that bind to SOS1 and activate nucleotide exchange on RAS. Using structure-based design, we refined the substituents attached to the quinazoline nucleus and built in additional interactions not present in the initial HTS hit. Optimized compounds activate nucleotide exchange at single-digit micromolar concentrations in vitro. In HeLa cells, these quinazolines increase the levels of RAS-GTP and cause signaling changes in the mitogen-activated protein kinase/extracellular regulated kinase (MAPK/ERK) pathway.

QUINAZOLINE COMPOUNDS AS MODULATORS OF RAS SIGNALING

The present invention relates to quinazoline compounds and compositions that modulate Ras signaling. Compounds and compositions of the present invention are useful in the treatment of cancers and other disease states associated with Ras dysfunction (e.g.,

CONDENSED-RING PYRIMIDYLAMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF

Disclosed are a condensed-ring pyrimidylamino derivative, a preparation method therefor, and an intermediate, a pharmaceutical composition and applications thereof. The method for preparing the condensed-ring pyrimidylamino derivative comprises: in a solvent, in the presence of a palladium-containing catalyst, allowing a compound represented by formula I-a and a compound represented by formula I-b' to have a coupling reaction, and then preparing a compound represented by formula I by means of a deprotection reaction. Also disclosed applications of the condensed-ring pyrimidylamino derivative in the preparation of drugs for preventing, relieving and/or treating tumors or diseases caused by an anaplastic lymphoma kinase. The condensed-ring pyrimidylamino derivative of the present invention has an obvious restraint effect on the anaplastic lymphoma kinase.

FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF

Disclosed area fused ring pyrimidine compound, and an intermediate, a preparation method, a composition and a use thereof. The fused ring pyrimidine compound is a compound as shown in formula I, a tautomer, an enantiomer, a diastereoisomer, a pharmaceutically acceptable salt, a metabolite, a metabolic precursor or a prodrug thereof, wherein the above-mentioned compound is used for the preparation of a medicine for preventing, remitting or treating one or more of immune system diseases, autoimmune diseases, cell proliferative diseases, allergic disorders and cardiovascular diseases, and the compound has a strong inhibitory effect on the Janues kinase, FGFR kinase, FLT3 kinase and Src family kinase.

CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS

Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.

CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS

Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.

The components of xRNA: Synthesis and fluorescence of a full genetic set of size-expanded ribonucleosides

The synthesis and properties of a full set of four benzo-expanded ribonucleosides (xRNA), analogous to A, G, C, and U RNA monomers, are described. The nucleosides are efficient fluorophores with emission maxima of 369-411 nm. The compounds are expected to